Navigation Links
Pharmion and MethylGene Announce U.S. Orphan Drug Designation Granted for MGCD0103 for the Treatment of Acute Myelogenous Leukemia
Date:2/14/2008

is characterized by the rapid proliferation (growth) of abnormal white blood cells. These cells are unable to perform their regular functions and eventually crowd out healthy red and white blood cells. Leukemia cells can also spread to other parts of the body. People afflicted with AML are susceptible to increased risk of infections, anemia and bleeding.

AML is the one of the most common forms of leukemia and occurs most often in older adults -- the average age being 65. The American Cancer Society estimates that 13,410 new cases and 8,990 deaths occurred in the United States in 2007.

Although several risk factors for AML have been identified, the specific cause of AML remains unclear. AML is a potentially curable disease; but only a minority of patients are cured with current therapies. Current treatments for AML include chemotherapy, blood transfusions and stem cell transplants.

About Pharmion

Pharmion is a leading global oncology company focused on acquiring, developing and commercializing innovative products for the treatment of hematology and oncology patients in the U.S., Europe and additional international markets. Pharmion has a number of products on the market including the world's first approved epigenetic drug, Vidaza(R), a DNA demethylating agent. For additional information about Pharmion, please visit the company's website at http://www.pharmion.com.

About MethylGene

MethylGene Inc. (TSX: MYG) is a publicly-traded biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for cancer. The Company's lead product, MGCD0103, is an oral isotype-selective HDAC inhibitor presently in multiple clinical trials for solid tumors and hematological malignancies, including Phase II monotherapy and Phase I and Phase II combination trials with Vidaza(R), Gemzar(R) and Taxotere(R). MGCD265 is an oral kinase inhibitor targeting t
'/>"/>

SOURCE Pharmion Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Pharmion and MethylGene Announce Orphan Drug Designation Granted by the European Medicines Agency (EMEA) for MGCD0103 for the Treatment of Acute Myelogenous Leukemia
2. Thalidomide Pharmion(R) Receives Positive Opinion for Treatment of First-line Multiple Myeloma from European Medicines Agency
3. Pharmion Submits European Marketing Authorization Application (MAA) for Vidaza(R) in Patients with Higher-Risk Myelodysplastic Syndromes (MDS)
4. Pharmion and MethylGene Start Phase 2 Combination Clinical Trial With MGCD0103 and Vidaza(R) in Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma
5. Pharmions Amrubicin Shows Encouraging Results Compared to Standard of Care in Second Line Treatment of Small Cell Lung Cancer
6. Pharmion and MethylGene Report Preliminary MGCD0103 Clinical Data at the 2007 AACR-NCI-EORTC International Conference
7. Pharmion Initiates Pivotal Phase 3 Study of Amrubicin in Small Cell Lung Cancer
8. Pharmion and MethylGene Initiate Phase One Combination Clinical Trial with MGCD0103 and Taxotere(R) in Patients with Solid Tumors
9. Pharmion and MethylGene Announce U.S. Orphan Drug Designation Granted for MGCD0103 for the Treatment of Hodgkins Lymphoma
10. Raven Announces Completion of Enrollment in the Phase 1/2a Clinical Trial of RAV12 Therapeutic Antibody for the Treatment of Adenocarcinomas
11. Watson Announces Silodosin NDA Accepted for Filing by FDA for the Treatment of Benign Prostatic Hyperplasia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... August 29, 2014 According ... Market by Extraction type (SFE, Cold Pressed, Organic ... Care, Pharmaceutical, Food Supplements, Fragrance, & Others) - Global ... defines and segments the Amaranth Seed Oil Market ... size in terms of value. The Amaranth Seed ...
(Date:8/29/2014)... 2014 According to the ... Services (Equipment, Reagent, Primer, Probe, Custom Oligos), End-User ... Gene Synthesis, NGS, DNA, RNAi) - Global Forecast ... Synthesis Market is expected to reach $1,712.1 Million ... at a CAGR of 9.8% from 2014 to ...
(Date:8/29/2014)... -- In part four of a blog series ... a strategic asset, Mary Baxter, MBA, RPh ., ... Innovation Delivery Solutions business, discusses how expanding patient access ... patients. "Every hospital pharmacist knows that filling ... in a value-based healthcare world," Baxter says. "For the ...
Breaking Medicine Technology:Amaranth Seed Oil Market worth $700.6 Million by 2019 2Amaranth Seed Oil Market worth $700.6 Million by 2019 3Amaranth Seed Oil Market worth $700.6 Million by 2019 4Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 2Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 3Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 4Five Ways Hospital Pharmacies Can Fulfill Their Quality Care Mission 2Five Ways Hospital Pharmacies Can Fulfill Their Quality Care Mission 3Five Ways Hospital Pharmacies Can Fulfill Their Quality Care Mission 4
... BioSpecifics Technologies Corp. (Nasdaq: BSTC ), a biopharmaceutical company ... Tom Wegman , will present at the upcoming Jefferies & Company 2010 ... 2:30pm EDT . , ... A live webcast of the presentation can be accessed under "Calendar ...
... Questcor Pharmaceuticals, Inc . (Nasdaq: QCOR ) announced today ... Thursday, June 10, 2010 at The Grand Hyatt Hotel in ... Executive Officer, will discuss the Company,s business strategy and historical financial performance at ... , , ...
Cached Medicine Technology:BioSpecifics Technologies Corp. to Present at Jefferies & Company 2010 Global Life Sciences Conference 2BioSpecifics Technologies Corp. to Present at Jefferies & Company 2010 Global Life Sciences Conference 3Questcor to Present at the Jefferies 2010 Global Life Sciences Conference 2
(Date:9/1/2014)... 01, 2014 Ontraport , one ... that was developed to automate the small intricacies of ... of Shane Michaels, prompting an investigative review. , ... duty of managing all of the small details involved ... overwhelming,” reports Michaels. “That’s why Ontraport has become so ...
(Date:9/1/2014)... 2014 AttorneyOne.com, a recognized authority on ... information from the FDA on DePuy Synthes Craniomaxillofacial ... on August 28, that specific lots of DePuy Synthes ... as the device may reverse directions after surgery. ... Distraction System is an implant used to lengthen and/or ...
(Date:9/1/2014)... Nevada (PRWEB) September 01, 2014 Beginning ... to over 3,000 medical professionals and 10,000 consumers for ... is a 5-day gathering of the nation’s top medical ... associated diseases or conditions. The week-long event contains more ... evidence-based scientific instruction available in the pain management field. ...
(Date:8/31/2014)... 31, 2014 An analysis of 32 ... has revealed a link between lower levels of Vitamin ... in the August 2014 issue of American ... main form of Vitamin D found in blood. ... 25-Hydroxyvitamin D lower than 9 nanograms/milliliter (ng/mL) were twice ...
(Date:8/31/2014)... (PRWEB) August 31, 2014 The FDA ... Nutrition Facts label. If adopted, the proposed changes would ... addition of “added sugars” on the label, and a ... to keep “added sugars” off the label. NutriGold fully ... consumers make healthier food choices. “After 20 years, it's ...
Breaking Medicine News(10 mins):Health News:Ontraport: Review Exposes Automated Platform for Online Marketing Management 2Health News:DePuy Synthes Craniomaxillofacial Distraction System Recalled (Class I): AttorneyOne Monitors and Keeps Consumers Informed 2Health News:DePuy Synthes Craniomaxillofacial Distraction System Recalled (Class I): AttorneyOne Monitors and Keeps Consumers Informed 3Health News:Medical Marijuana Doctor Company Set to Present at Las Vegas Pain Week 2Health News:NutriGold Highlights New Study on the Importance of Vitamin D to Our Life Span 2Health News:NutriGold Highlights New Study on the Importance of Vitamin D to Our Life Span 3Health News:NutriGold Highlights New Study on the Importance of Vitamin D to Our Life Span 4Health News:NutriGold Supports the FDA's Call for an Updated Nutrition Facts Label 2Health News:NutriGold Supports the FDA's Call for an Updated Nutrition Facts Label 3Health News:NutriGold Supports the FDA's Call for an Updated Nutrition Facts Label 4
... of a new use for magnetic levitation, or "maglev," ... trains to float above the tracks. In ACS, bi-weekly ... describe putting maglev to use in an inexpensive sensor ... Whitesides and colleagues note that measurements of a substance,s ...
... in Spanish . Ensuring the optimum ... in prostate cancer treatment manages to control the illness in ... research undertaken at the University Hospital of Navarre and published ... the American Society of Brachytherapy. As is known, brachytherapy ...
... (June 23, 2010) Children who experience maltreatment ... likely to experience frequent headaches, including chronic migraine, as ... Headache Society,s 52nd Annual Scientific Meeting in Los Angeles ... Experiences (ACE) Study of 17,337 adult members of the ...
... Some 19 percent of soldiers returning from Iraq have ... While prevalence of migraine among the U.S. military ... quality in soldiers with chronic headaches including post-traumatic headache ... Army Medical Center in Tacoma, WA presenting at American ...
... having the most expensive health care system, the United ... countriesAustralia, Canada, Germany, the Netherlands, New Zealand, and the ... areas: quality, efficiency, access to care, equity and the ... a new Commonwealth Fund report. While there is room ...
... research professor in the department of physics at NJIT, ... Research Council (NRC) of the National Academies ( www.nationalacademies.org ... vehicles in the aftermath of Toyota,s large recalls. The ... and July 1, 2010 in Washington, DC, includes notable ...
Cached Medicine News:Health News:Optimizing brachytherapy dose on the same day as the implant can control prostate cancer 2Health News:US ranks last among 7 countries on health system performance 2Health News:US ranks last among 7 countries on health system performance 3Health News:NJIT professor heads panel studying sudden car acceleration 2
The modular, high-end stereomicroscope; meets even the most critical demands in research and quality control provides high-contrast images with excellent depth of field and color fidelity...
6.3X Zoom Ratio - Boasting magnifications from 0.8X to 5X, the twin zooming objective optical system developed exclusively by Nikon provides a zoom ratio of 6.3:1. Clickstops at 1X intervals allow ob...
Fixed Versatility - With a diverse selection of body tubes, stands, lighting techniques and Nikon's world-renowned optics, this modular microscope can be configured to fit nearly any application....
... designed to have the following properties and ... sections, cell cultures, specimens with aqueous embedding ... cover glass thickness (0.14...0.18 mm) and temperatures ... correction collar can also be used for ...
Medicine Products: